Patents by Inventor Michelle A. Hurchla Pyles

Michelle A. Hurchla Pyles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9045562
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: June 2, 2015
    Assignee: Washington University
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • Patent number: 8546541
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: October 1, 2013
    Assignee: Washington University
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • Publication number: 20120322986
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: May 17, 2012
    Publication date: December 20, 2012
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • Publication number: 20120207759
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: December 30, 2011
    Publication date: August 16, 2012
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • Publication number: 20110230647
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: December 23, 2010
    Publication date: September 22, 2011
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang